Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, multicentre, randomized controlled trial of MIP-1095-I-131 in combination with enzalutamide in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)

Trial Profile

A phase II, multicentre, randomized controlled trial of MIP-1095-I-131 in combination with enzalutamide in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Enzalutamide (Primary) ; MIP 1095-I-131 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2018 New trial record
    • 11 Oct 2018 According to a Progenics Pharmaceuticals media release, the company expects to begin enrollment of approximately 120 evaluable patients in the study in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top